Balyasny Asset Management
EPZM

Balyasny Asset Management’s Epizyme, Inc EPZM Stock Holding History

Balyasny Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25,990
Closed -$65K – 3031
2021
Q4 		$65K Buy
+25,990
New +$102K ﹤0.01% 2032
2020
Q2 		– Sell
-29,557
Closed -$458K – 1598
2020
Q1 		$458K Buy
+29,557
New +$635K 0.01% 923
2015
Q4 		– Sell
-652,472
Closed -$8.39M – 1518
2015
Q3 		$8.39M Sell
652,472
-209,155
-24% -$4.22M 0.06% 387
2015
Q2 		$20.7M Buy
861,627
+359,596
+72% +$6.92M 0.13% 208
2015
Q1 		$9.43M Buy
+502,031
New +$10.4M 0.08% 349

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's EPZM Position: Q1 2022 in Review

Balyasny Asset Management sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 25,990 shares — an estimated $65K sold.

Balyasny Asset Management first reported a position in EPZM in Q1 2015 and held it in 5 quarters. The position peaked at $20.7M in Q2 2015. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Balyasny Asset Management reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 25,990 Epizyme, Inc shares in Q1 2022, an estimated $65K.
  • Balyasny Asset Management first reported a position in Epizyme, Inc in Q1 2015 and held it in 5 quarters.
  • Balyasny Asset Management's Epizyme, Inc position peaked at $20.7M in Q2 2015.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Balyasny Asset Management's 13F filing for Q1 2022, filed 16 May 2022.